Literature DB >> 11261820

Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver.

Y Nakanuma1, K Tsuneyama, M Ohbu, K Katayanagi.   

Abstract

Idiopathic portal hypertension (IPH) is characterized by a long-standing presinusoidal portal hypertension of unknown etiology in adults. Some unidentified agent(s) affect(s) the intrahepatic small portal veins or portal tracts. Immunological disturbance, thromboembolism, infectious etiology and/or increased fibrogenesis in portal tracts are suspected as being candidates for the primary agent(s). During the long clinical course of IPH, several pathological changes may occur, including subcapsular parenchymal atrophy, atrophy of the liver, portal and parenchymal fibrosis, and portal venous phlebosclerosis and thrombosis. The last-named of these lesions is mostly found in patients with a history of splenectomy. Subcapsular parenchymal and hepatic atrophy may result from a hepatocellular dropout via apoptosis or necrosis because of intrahepatic hemodynamic disturbances, particularly chronic portal venous blood insufficiency. Pericellular fibrosis and thin fibrous septa are also frequently found and associated with activated perisinusoidal cells positive for smooth muscle actin. At the same time, vague nodular hyperplasia of hepatocytes not surrounded by fibrous septa is not infrequently seen. It may resemble nodular regenerative hyperplasia, partial nodular transformation, or focal nodular hyperplasia. However, liver cirrhosis does not occur even at the terminal stage. Taking these findings into consideration, a new staging of IPH with a combination of hepatic parenchymal atrophy and portal venous thrombosis was proposed: non-atrophic liver without subcapsular parenchymal atrophy (stage I), non-atrophic liver with subcapsular parenchymal atrophy (stage II), atrophic liver with subcapsular parenchymal atrophy (stage III), and portal venous occlusive thrombosis (stage IV). IPH livers are likely to progress from stage I to stage III. Stage IV, which occurs relatively late, has a poor prognosis. This staging is applicable to clinical and autopsy cases without any histological data.

Entities:  

Mesh:

Year:  2001        PMID: 11261820     DOI: 10.1078/0344-0338-5710012

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  18 in total

1.  Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies.

Authors:  Y Sato; X S Ren; K Harada; M Sasaki; H Morikawa; S Shiomi; M Honda; S Kaneko; Y Nakanuma
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 2.  Clinical characteristics of idiopathic portal hypertension.

Authors:  Ozgur Harmanci; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

3.  Hepatobiliary quiz-12 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12

Review 4.  Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and Emerging Newer Treatment Options.

Authors:  Ashish Goel; Joshua E Elias; Chundamannil E Eapen; Banumathi Ramakrishna; Elwyn Elias
Journal:  J Clin Exp Hepatol       Date:  2014-07-28

Review 5.  The current clinical aspects of idiopathic portal hypertension.

Authors:  Tomohiro Tanaka; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2013-08

6.  Intrahepatic periportal high intensity on hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI: imaging findings and prevalence in various hepatobiliary diseases.

Authors:  Satoshi Kobayashi; Osamu Matsui; Toshifumi Gabata; Wataru Koda; Tetsuya Minami; Kazuto Kozaka; Azusa Kitao; Norihide Yoneda; Kotaro Yoshida
Journal:  Jpn J Radiol       Date:  2012-10-03       Impact factor: 2.374

Review 7.  Pathology of idiopathic non-cirrhotic portal hypertension.

Authors:  Maria Guido; Samantha Sarcognato; Diana Sacchi; Guido Colloredo
Journal:  Virchows Arch       Date:  2018-04-12       Impact factor: 4.064

8.  Peliosis hepatis as an early histological finding in idiopathic portal hypertension: A case report.

Authors:  Annalisa Berzigotti; Donatella Magalotti; Paola Zappoli; Cristina Rossi; Francesco Callea; Marco Zoli
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

9.  Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension.

Authors:  Azusa Kitao; Yasunori Sato; Seiko Sawada-Kitamura; Kenichi Harada; Motoko Sasaki; Hiroyasu Morikawa; Susumu Shiomi; Masao Honda; Osamu Matsui; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

10.  Does endothelium agree with the concept of idiopathic hepatic vessel thrombosis?

Authors:  Ozgur Harmanci; Yahya Buyukasik; Serafettin Kirazli; Ferhun Balkanci; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.